EE329 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons
Abstract
Authors
J. Mestre-Ferrandiz V. Navarro-Compán Y Ivanova A. González-Domínguez S Maratia